Study of NM8074 in Soliris-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
The proposed study, NM8074-PNH-101, is a phase II, open-label, multi-dose, unicenter trial to
evaluate the safety and efficacy of NM8074 in Soliris-treated PNH subjects.